

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited
華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

- (1) RESIGNATION OF EXECUTIVE DIRECTOR AND
CHIEF EXECUTIVE OFFICER;**
**(2) APPOINTMENT OF EXECUTIVE DIRECTOR AND
CHIEF EXECUTIVE OFFICER;**
(3) CHANGE OF AUTHORIZED REPRESENTATIVE;
**(4) APPOINTMENT OF INDEPENDENT
NON-EXECUTIVE DIRECTOR;**
AND
(5) CHANGES IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces the following changes in the composition of the Board and its certain committees that, with effect from February 27, 2023: (1) Mr. CHENG Libing has resigned as an executive Director, the chief executive officer of the Company and an Authorized Representative; (2) Mr. YU Hai has been appointed as an executive Director and the chief executive officer of the Company; (3) Mr. SONG Qing has been appointed as an Authorized Representative; (4) Mr. LEE Kar Chung Felix has resigned as a member of the Audit Committee; (5) Mr. HU Hui has resigned as a member of the Remuneration Committee; and (6) Mr. FU Tingmei has been appointed as an independent non-executive Director, a member of the Audit Committee and a member of the Remuneration Committee.

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. CHENG Libing (“**Mr. CHENG**”) has resigned, with effect from February 27, 2023, as an executive Director, the chief executive officer of the Company and an authorized representative of the Company (“**Authorized Representative**”) due to personal pursuit. Mr. CHENG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his resignations which needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Mr. CHENG for his most valuable efforts and contributions to the Group during his tenure of office as an executive Director and various management positions within the Group.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. YU Hai (“**Mr. YU**”) has been appointed as an executive Director and the chief executive officer of the Company with effect from February 27, 2023.

Mr. YU, aged 55, is currently the general manager of China Resources Health Group Limited (華潤健康集團有限公司), and served as the vice chairman and senior vice general manager of China Resources Health Group Limited from January 2020 to February 2023 and as the chairman of Liaoning Healthcare Industry Group Co., Ltd. (遼寧省健康產業集團有限公司) from July 2018 to January 2020. Mr. YU worked in Benxi Municipal Government, Liaoning Province from July 2008 to July 2018, and served as the deputy mayor of Benxi City etc. Prior to that, Mr. YU held various positions at government departments including the deputy director of the Social Development Division of the Department of Science & Technology of Liaoning Province, the deputy director of the High-tech Development and Industrialization Division of the Department of Science & Technology of Liaoning Province, the deputy director of the Bureau of Science and Technology of Nagchu District, the Tibet Autonomous Region, and the principal officer of the Industrial and Social Development Division, the Scientific and Technological Commission of Liaoning Province etc. Mr. YU holds a doctor of science degree in pharmaceutical affairs management from the School of Pharmacy, Shenyang Pharmaceutical University (瀋陽藥科大學).

Mr. YU has entered into a service agreement with the Company for a term of three years commencing from February 27, 2023, which can be terminated by either party by giving to the other party not less than one month's notice in writing. Mr. YU shall not receive any basic salary from the Company as an executive Director, but the Board has resolved that Mr. YU shall be entitled to the discretionary bonus at the sole and absolute discretion of the Board and the remuneration committee of the Company (“**Remuneration Committee**”) (depending on the Board's corporate goals and objectives, salaries paid by comparable companies, time commitment, responsibilities, employment conditions and performance of the Company and the individual Director). The aforesaid proposal on the emolument of Mr. YU was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

Pursuant to the articles of association of the Company, Mr. YU will hold office as an executive Director until the next general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

As at the date of this announcement, Mr. YU does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, Mr. YU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; and (iv) does not have any other major appointments or professional qualifications.

Save as disclosed in this announcement, there is no further information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Mr. YU that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Mr. YU for his new appointment.

APPOINTMENT OF AUTHORIZED REPRESENTATIVE

The Board is pleased to announce that Mr. SONG Qing, the chairman of the Board and an executive Director, will also serve as an Authorized Representative with effect from February 27, 2023.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. FU Tingmei (“**Mr. FU**”) has been appointed as an independent non-executive Director with effect from February 27, 2023.

Mr. FU, aged 56, currently serves as an independent non-executive director of the following companies which are listed on the Stock Exchange: China Resources Pharmaceutical Group Limited (stock code: 3320), Guotai Junan International Holdings Limited (stock code: 1788), Postal Savings Bank of China Co., Ltd. (stock code: 1658) and COFCO Joycome Foods Limited (stock code: 1610). Mr. FU was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017 and an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019. Mr. FU has over 30 years of experience in investment, finance, law and business management. Mr. FU holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.

Mr. FU has entered into a letter of appointment with the Company for a term from February 27, 2023 to February 26, 2026, which can be terminated by either party by giving to the other party not less than one month’s notice in writing. The Board has resolved that Mr. FU will be entitled to a director fee of HKD300,000 per annum, which was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

Pursuant to the articles of association of the Company, Mr. FU will hold office as an independent non-executive Director until the next annual general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

Save as disclosed in this announcement, Mr. FU (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

As at the date of this announcement, Mr. FU does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and has met the independence criteria as set out in Rule 3.13 of the Listing Rules.

Save as disclosed in this announcement, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. FU that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby expresses its warmest welcome to Mr. FU for his new appointment.

CHANGES IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that Mr. LEE Kar Chung Felix has resigned as a member of the audit committee of the Company (“**Audit Committee**”), Mr. HU Hui has resigned as a member of the Remuneration Committee and Mr. FU Tingmei has been appointed as a member of the Audit Committee and a member of the Remuneration Committee with effect from February 27, 2023.

By order of the Board
China Resources Medical Holdings Company Limited
SONG Qing
Chairman

Shenzhen, February 27, 2023

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. YU Hai, Ms. REN Yuan and Mr. SHAN Baojie as executive Directors; Mr. HU Hui as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Mr. LEE Kar Chung Felix and Mr. FU Tingmei as independent non-executive Directors.